Immunoglobulin G1, anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal SHR-1805 ?1-chain), complex with human-Mus musculus monoclonal SHR-1805 ?-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide
Metastatic Neoplasm
Jiangsu HengRui Medicine Co., Ltd.antibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
144 Active assets in the Metastatic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Xaliplatin Ruijin Hospital | Phase 4 | BBB |
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
Dexasone Janssen Research & Development, LLC | Phase 2 | BBB |
Atezolizumab UNC Lineberger Comprehensive Cancer Center | Phase 2/3 | BB |
View all 49 →
Same molecule, other indications
Immunoglobulin G1, anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal SHR-1805 ?1-chain), complex with human-Mus musculus monoclonal SHR-1805 ?-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →